Abstract

Title: Cannabinoid receptor ligands prevent dopaminergic neurons death induced by neurotoxic, inflammatory and oxidative stimuli in vitro. Background: During the last 25 years increasing efforts have been invested for the comprehension of the cannabinoid system in a wide range of healthy and pathological conditions. Previous investigations have indicated the possible protective role of synthetic cannabinoids like arachidonyl-2’-chloroethylamide, ACEA (CB1 agonist), during neurodegenerative diseases such as Parkinson’s disease. Other synthetic CB1 receptor ligands such as N-(Piperidin-1-yl)-5-(4- iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide, AM251, commonly known as an antagonist/inverse agonist, have recently been presented as an allosteric modulator of this receptor. In this study, we show the protective effect of ACEA against oxidative and inflammatory damage in in vitro dopaminergic neurons. Methods and Findings: Neuro2A cells differentiated into dopaminergic-like neurons were challenged with neurotoxic, inflammatory and oxidative treatments, 6-hydroxidopamine (6OHDA), lipopolysaccharide (LPS) and hydrogen peroxide (H2O2). Cannabinoid-dependent cell protection was evaluated by means of cellular viability, reactive oxygen species (ROS) production and the pro apoptotic protein caspase 3 expression after CB1 agonist ACEA and antagonist AM251. The ACEA treatment resulted in an increase of cellular viability after the 6OHDA, LPS and H2O2 challenges. When cells were co-treated with ACEA and AM251, an increase in cell death prevention was observed, with a reduction in reactive oxygen species production and caspase 3 expression. Conclusions: Together, we show an ACEA-mediated neuronal protection by means of ROS expression reduction and pro apoptotic protein caspase 3 expression inhibition.

Highlights

  • The endocannabinoid system is present in all mammals, widespread for the whole body with different functions

  • Dibutyryladenosine-3’, 5’- cyclic monophosphate (DbcAMP), 6OHDA, ACEA (KD/I CB1 receptor 1.4 nM) [25] AM251 (KD/I CB1 receptor 7.49 nM), dihydroethidium (DHE) and LPS were used in this study; all reagents were from Sigma (St Louis, MO, USA)

  • 2 μM of ACEA treatment was able to prevent, at least partially, the cells from death induced by 6OHDA (12% cell death), LPS (10% cell death) or H2O2 (7% cell death)

Read more

Summary

Introduction

The endocannabinoid system is present in all mammals, widespread for the whole body with different functions. The cannabinoids signaling has been implicated in several processes both in healthy and pathological brain. Increased and decreased levels of endocannabinoids and changes in the expression of CB1 receptors in brain damage models in rats and mice have been demonstrated [9,10,11,12,13,14,15,16]. In human brain of patients with neurodegenerative diseases, such as Huntington’s and Parkinson’s disease [17,18] have been shown altered levels of endocannabinoid, despite that, cannabinoids have provided symptomatic relief in experimental models of chronic neurodegenerative diseases [19]. Previous investigations have indicated the possible protective role of synthetic cannabinoids like arachidonyl-2’-chloroethylamide, ACEA (CB1 agonist), during neurodegenerative diseases such as Parkinson’s disease. We show the protective effect of ACEA against oxidative and inflammatory damage in in vitro dopaminergic neurons

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.